First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2014-10-01 21:56:22Open Document File Size: 32,91 KBShare Result on FacebookCompanySanofi-Aventis Australia Pty Ltd / PBAC / Genzyme / /CountryGermany / United States / Netherlands / Canada / Australia / United Kingdom / /CurrencyUSD / /FacilityErasmus Medical Centre / /IndustryTermrehabilitative services / therapy for patients with Pompe disease / treatment of late onset Pompe disease / /MedicalConditioninherited disorder / rapidly progressive disease / acid alfa-glucosidase deficiency / progressive muscle weakness / disease / Proposed Therapy Pompe disease / cardiac failure / single disease / late-onset Pompe disease / annual questionnaire assessing disease / steadily progressive disease / treatment of late onset Pompe disease / late onset Pompe disease / infantile-onset Pompe disease / Pompe disease / /OrganizationAustralasian Society for Inborn Errors / Pharmaceutical Benefits Advisory Committee / Erasmus Medical Centre / Division of Sanofi-Aventis Australia Pty Ltd / Australian Government / Department of Veterans Affairs / Metabolism/ Australia New Zealand Association of Neurologists / International Pompe Association / /PositionGovernor / /ProductMyozyme / /URLhttp /SocialTag |